On September 3, 2019 Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (sd-rxRNA) therapeutic platform, announced today that it will present at the H.C. Wainwright 21st Annual Healthcare Conference in New York City (Press release, Phio Pharmaceuticals, SEP 3, 2019, View Source [SID1234539207]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Gerrit Dispersyn, Dr. Med. Sc., President and CEO, will present an overview of the Company’s RNAi technology and an update on the Company’s development activities. The presentation will be held September 10, 2019, at 11:40 AM in the Kennedy II room (4th Floor) at the Lotte New York Palace Hotel. Dr. Dispersyn will also be available for investor and executive meetings throughout the conference.

The presentation will be webcast live and archived under the "Investors – Events and Presentations" section of the Company’s website, www.phiopharma.com.